EVALUATION OF ANTI-ANXIETY EFFECT OF NIFEDIPINE COMPARED TO DIAZEPAM IN SWISS ALBINO MICE USING BEHAVIOURAL MODELS
Introduction: Anxiety is a psychological and physiological state characterized by somatic, emotional, cognitive, and behavioural components with displeasing feeling of fear and concern. Among all the antianxiety drugs benzodiazepines are commonly employed drugs for the treatment but they do have limitations. Considering the high prevalence of anxiety disorders and lack of an ideal anxiolytic drug, search for better anxiolytic drugs continue. Hence this study was undertaken to evaluate the acute and chronic anxiolytic effects of Nifedipine in comparison to Diazepam using in Swiss Albino mice using two behavioural models
Methods: 30 Swiss Albino mice were divided into 5 groups with 6 mice in each group. The study was conducted in two phases to evaluate the acute & chronic effects. The groups consisted of Diazepam(1mg/kg), 3 doses of Nifedipine (2.6mg/kg, 5.2mg/kg & 10.4mg/kg) & vehicle control. The elevated plus maze and light & dark box was used to evaluate the anti-anxiety effects. The number of entries and time spent in open arm of Elevated Plus maze and in light area of Light and dark box model were noted and compared among the 5 groups. Observations were analysed using ANOVA and Post hoc Tukey’s test.
Results: Medium & high doses of Nifedipine significantly increased the number of entries and time spent in open arm and light area in both models (p<0.05).
Conclusion: Two doses of Nifedipine possess anti-anxiety effects both on acute and chronic administration in both Elevated Plus maze & Light and dark box model.
KEYWORDS: Anxiolytic, dihydropyridines, behavioural model, mice
2. Olatunji BO, Cisler JM, Tolin DF. Quality of life in anxiety disorders: a meta- analytic review. Clin Psychol Review. 2007; 27:572-581
3. Shri R. Anxiety: causes and management. International Journal of Behavioral Science (IJBS). 2010;5(1).
4. Manavi C, Rajkumar V, Vijai L. Anxiolytic effects of plumeria rubra var. Acutifolia (poiret) L. Flower extracts in the elevated plus-maze model of anxiety in mice. Asian J Psychiat. 2013;6:113–8.
5. Mahendra P, Bisht S. Anti-anxiety activity of Coriandrum sativum assessed using different experimental anxiety models. Indian J Pharmacol. 2011;43(5):574-7
6. Soodan S, Arya A. Understanding the Pathophysiology and Management of the Anxiety disorders. International Journal of Pharmacy and Pharmaceutical Research. 2015 Oct;4(3):251-78.
7. Catterall WA. Voltage-Gated Calcium Channels. Cold Spring Harbor Perspectives in Biology. 2011 Aug;3(8):1-23
8. Elliott WJ, Ram CV. Calcium channel blockers. The Journal of Clinical Hypertension. 2011;13(9):687-9.
9. Larkin JG, Thompson GG, Scobie G, Forrest G, Drennan JE, Brodie MJ. Dihydropyridine calcium antagonists in mice: blood and brain pharmacokinetics and efficacy against pentylenetetrazol seizures. Epilepsia. 1992 1;33(4):760-9.
10. El Ganouni S, Tazi A, Hakkou F. Potential serotonergic interactions with the anxiolytic-like effects of calcium channel antagonists. Pharmacology Biochemistry and Behavior. 1998;60(2):365-9.
11. Umukoro S, Ashorobi RB, Essein EE. Anticonvulsant and anxiolytic effects of calcium channel blockers in mice. J. Med. Sci. 2006;6(5):1021-4.
12. Tanwani H, Nyati P, Atal S, Churihar R. Evaluation of antianxiety, antidepressant and sedative effects of nimodipine in swiss albino mice. International Journal of Pharmacy and Pharmaceutical Sciences. 2016 ;8(6):260-3.
13. Goodman L, Gilman A, Brunton L, Hilal-Dandan R, Knollmann B. Goodman & Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill Education; 2018.
14. Sreedharan N, Rao PG, Rau NR, Shankar PR. Antihypertensive prescribing preferences in three South Indian Hospitals: cost analysis, physicians perspectives and emerging trends. International Journal of Clinical Pharmacology and Therapeutics. 2011;49(4):277.
15. Gupta R, Malhotra A, Malhotra P. Study of prescribing pattern of drugs used in the treatment of hypertension in a tertiary care teaching hospital in North India: an observational study. International Journal of Research in Medical Sciences. 2018;6(7).
16. Sweetman SC. Martindale: The Complete Drug Reference. 36th Edition. London: Pharmaceutical Press; 2009. Cardiovascular drugs.
17. Nishino T, Takeuchi T, Takechi K, Kamei C. Evaluation of anxiolytic-like effects of some short-acting benzodiazepine hypnotics in mice. Journal of pharmacological sciences. 2008;107(3):349-54.
18. Walf AA, Frye CA. The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nature protocols. 2007 ;2(2):322-8.
19. Bourin M, Hascoët M. The mouse light/dark box test. European journal of pharmacology. 2003;463(1-3):55-65.
20. Moser DK. “The rust of life”: impact of anxiety on cardiac patients. American Journal of Critical Care. 2007;16(4):361-9.
21. Uchida S, Yamada S, Nagai K, Deguchi Y, Kimura R. Brain pharmacokinetics and in vivo receptor binding of 1, 4-dihydropyridine calcium channel antagonists. Life sciences. 1997;61(21):2083-90
22. Ninan PT. The functional anatomy, neurochemistry, and pharmacology of anxiety. The Journal of clinical psychiatry. 1999.
23. Cortes R, Supavilai P, Karobath M, Palacios JM. Calcium antagonist binding sites in the rat brain: quantitative autoradiographic mapping using the 1, 4-dihydropyridines [3 H] PN 200-110 and [3 H] PY 108-068. Journal of neural transmission. 1984;60(3-4):169-97.
24. Feder A, Costi S, Iacoviello B, Murrough J, Charney D. Anxiety Disorders: Neurobiology and Neuroscience. In: B. Sadock, V. Sadock and P. Ruiz, ed., Kaplan and Sadock's Comprehensive textbook of psychiatry, 10th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins.
25. Pan Y, Cai W, Cheng Q, Dong W, An T, Yan J. Association between anxiety and hypertension: a systematic review and meta-analysis of epidemiological studies. Neuropsychiatric disease and treatment. 2015;11:1121.
This work is licensed under a Creative Commons Attribution 4.0 International License.